Stopping lopinavir/ritonavir in COVID-19 patients: duration of the drug interacting effect

被引：50
|
作者：
Stader, Felix [1 ,2 ,3 ]
Khoo, Saye [4 ]
Stoeckle, Marcel [1 ,2 ,3 ]
Back, David [4 ]
Hirsch, Hans H. [1 ,2 ,5 ]
Battegay, Manuel [1 ,2 ,3 ]
Marzolini, Catia [1 ,2 ,3 ,4 ]
机构：
[1] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Med, Basel, Switzerland
[2] Univ Hosp Basel, Div Infect Dis & Hosp Epidemiol, Dept Clin Res, Basel, Switzerland
[3] Univ Basel, Basel, Switzerland
[4] Univ Liverpool, Inst Translat Med, Dept Mol & Clin Pharmacol, Liverpool, Merseyside, England
[5] Univ Basel, Dept Biomed, Transplantat & Clin Virol, Basel, Switzerland
来源：
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY | 2020年 / 75卷 / 10期
关键词：
ENZYMES; CYP1A2; CYP3A4;
D O I：
10.1093/jac/dkaa253
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：3084 / 3086
页数：3
相关论文
共 50 条
  • [21] Adverse effects of lopinavir/ritonavir in critically ill patients with COVID-19
    Vecchio, Gisela
    Zapico, Valeria
    Catanzariti, Alejandro
    Carboni Bisso, Indalecio
    Las Heras, Marcos
    MEDICINA-BUENOS AIRES, 2020, 80 (05) : 439 - 441
  • [22] Lopinavir/ritonavir in COVID-19 patients: maybe yes, but at what dose?
    Baldelli, Sara
    Corbellino, Mario
    Clementi, Emilio
    Cattaneo, Dario
    Gervasoni, Cristina
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2020, 75 (09) : 2704 - 2706
  • [23] BET 1: LOPINAVIR-RITONAVIR AND COVID-19
    Dolan, Daniel
    Ingham, Jack
    Baombe, Janos
    EMERGENCY MEDICINE JOURNAL, 2020, 37 (07) : 450 - +
  • [24] A Trial of Lopinavir-Ritonavir in Covid-19 Reply
    Cao, Bin
    Zhang, Dingyu
    Wang, Chen
    NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (21):
  • [25] No Benefit for Lopinavir-Ritonavir in Severe COVID-19
    Slomski, Anita
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2020, 323 (20): : 1999 - 1999
  • [26] Lopinavir / ritonavir for COVID-19: A living systematic review
    Verdugo-Paiva, Francisca
    Izcovich, Ariel
    Ragusa, Martin
    Rada, Gabriel
    MEDWAVE, 2020, 20 (06):
  • [27] Pharmacokinetics of Lopinavir and Ritonavir in Patients Hospitalized With Coronavirus Disease 2019 (COVID-19)
    Schoergenhofer, Christian
    Jilma, Bernd
    Stimpfl, Thomas
    Karolyi, Mario
    Zoufaly, Alexander
    ANNALS OF INTERNAL MEDICINE, 2020, 173 (08) : 670 - +
  • [28] High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment
    Macias, Juan
    Pinilla, Ana
    Lao-Dominguez, Francisco A.
    Corma, Anais
    Contreras-Macias, Enrique
    Gonzalez-Serna, Alejandro
    Gutierrez-Pizarraya, Antonio
    Fernandez-Fuertes, Marta
    Morillo-Verdugo, Ramon
    Trigo, Marta
    Real, Luis M.
    Pineda, Juan A.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [29] Maculopapular rash in COVID-19 patient treated with lopinavir/ritonavir
    Mazan, Paula
    Lesiak, Aleksandra
    Skibinska, Malgorzata
    Kamerys, Juliusz
    Czajkowski, Rafal
    Owczarek, Witold
    Narbutt, Joanna
    POSTEPY DERMATOLOGII I ALERGOLOGII, 2020, 37 (03): : 435 - 437
  • [30] Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
    Zhu, Zhen
    Lu, Zhaohui
    Xu, Tianmin
    Chen, Cong
    Yang, Gang
    Zha, Tao
    Lu, Jianchun
    Xue, Yuan
    JOURNAL OF INFECTION, 2020, 81 (01) : E21 - E23
12345